Literature DB >> 20735442

Germline mutation in BRAF codon 600 is compatible with human development: de novo p.V600G mutation identified in a patient with CFC syndrome.

K J Champion1, C Bunag, A L Estep, J R Jones, C H Bolt, R C Rogers, K A Rauen, D B Everman.   

Abstract

BRAF, the protein product of BRAF, is a serine/threonine protein kinase and one of the direct downstream effectors of Ras. Somatic mutations in BRAF occur in numerous human cancers, whereas germline BRAF mutations cause cardio-facio-cutaneous (CFC) syndrome. One recurrent somatic mutation, p.V600E, is frequently found in several tumor types, such as melanoma, papillary thyroid carcinoma, colon cancer, and ovarian cancer. However, a germline mutation affecting codon 600 has never been described. Here, we present a patient with CFC syndrome and a de novo germline mutation involving codon 600 of BRAF, thus providing the first evidence that a pathogenic germline mutation involving this critical codon is not only compatible with development but can also cause the CFC phenotype. In vitro functional analysis shows that this mutation, which replaces a valine with a glycine at codon 600 (p.V600G), leads to increased ERK and ELK phosphorylation compared to wild-type BRAF but is less strongly activating than the cancer-associated p.V600E mutation.
© 2010 John Wiley & Sons A/S.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 20735442     DOI: 10.1111/j.1399-0004.2010.01495.x

Source DB:  PubMed          Journal:  Clin Genet        ISSN: 0009-9163            Impact factor:   4.438


  10 in total

1.  Germline De Novo Mutations in GNB1 Cause Severe Neurodevelopmental Disability, Hypotonia, and Seizures.

Authors:  Slavé Petrovski; Sébastien Küry; Candace T Myers; Kwame Anyane-Yeboa; Benjamin Cogné; Martin Bialer; Fan Xia; Parisa Hemati; James Riviello; Michele Mehaffey; Thomas Besnard; Emily Becraft; Alexandrea Wadley; Anya Revah Politi; Sophie Colombo; Xiaolin Zhu; Zhong Ren; Ian Andrews; Tracy Dudding-Byth; Amy L Schneider; Geoffrey Wallace; Aaron B I Rosen; Susan Schelley; Gregory M Enns; Pierre Corre; Joline Dalton; Sandra Mercier; Xénia Latypova; Sébastien Schmitt; Edwin Guzman; Christine Moore; Louise Bier; Erin L Heinzen; Peter Karachunski; Natasha Shur; Theresa Grebe; Alice Basinger; Joanne M Nguyen; Stéphane Bézieau; Klaas Wierenga; Jonathan A Bernstein; Ingrid E Scheffer; Jill A Rosenfeld; Heather C Mefford; Bertrand Isidor; David B Goldstein
Journal:  Am J Hum Genet       Date:  2016-04-21       Impact factor: 11.025

2.  Ultra-sensitive Sequencing Identifies High Prevalence of Clonal Hematopoiesis-Associated Mutations throughout Adult Life.

Authors:  Rocio Acuna-Hidalgo; Hilal Sengul; Marloes Steehouwer; Maartje van de Vorst; Sita H Vermeulen; Lambertus A L M Kiemeney; Joris A Veltman; Christian Gilissen; Alexander Hoischen
Journal:  Am J Hum Genet       Date:  2017-06-29       Impact factor: 11.025

3.  Cotreatment of hairy cell leukemia and melanoma with the BRAF inhibitor dabrafenib.

Authors:  James S Blachly; Gerard Lozanski; David M Lucas; Michael R Grever; Kari Kendra; Leslie A Andritsos
Journal:  J Natl Compr Canc Netw       Date:  2015-01       Impact factor: 11.908

4.  RAS/BRAF mutational status in familial non-medullary thyroid carcinomas: A retrospective study.

Authors:  Matteo Landriscina; Maria Iole Natalicchio; Olga Lamacchia; Antonella Conserva; Annamaria Piscazzi; Anna Ciampolillo; Matteo Zingrillo; Antonio Pennella; Pantaleo Bufo; Giulia Vita; Raffaele Antonetti; Eugenio Maiorano; Francesco Giorgino; Mauro Cignarelli
Journal:  Oncol Lett       Date:  2015-06-17       Impact factor: 2.967

5.  The intermediate-activity (L597V)BRAF mutant acts as an epistatic modifier of oncogenic RAS by enhancing signaling through the RAF/MEK/ERK pathway.

Authors:  Catherine Andreadi; Lai-Kay Cheung; Susan Giblett; Bipin Patel; Hong Jin; Kathryn Mercer; Tamihiro Kamata; Pearl Lee; Alexander Williams; Martin McMahon; Richard Marais; Catrin Pritchard
Journal:  Genes Dev       Date:  2012-08-14       Impact factor: 11.361

6.  The yin-yang of kinase activation and unfolding explains the peculiarity of Val600 in the activation segment of BRAF.

Authors:  Christina Kiel; Hannah Benisty; Veronica Lloréns-Rico; Luis Serrano
Journal:  Elife       Date:  2016-01-08       Impact factor: 8.140

Review 7.  Skin Pigmentation Abnormalities and Their Possible Relationship with Skin Aging.

Authors:  Ai-Young Lee
Journal:  Int J Mol Sci       Date:  2021-04-02       Impact factor: 5.923

8.  MiRNA therapeutics based on logic circuits of biological pathways.

Authors:  Valeria Boscaino; Antonino Fiannaca; Laura La Paglia; Massimo La Rosa; Riccardo Rizzo; Alfonso Urso
Journal:  BMC Bioinformatics       Date:  2019-11-22       Impact factor: 3.169

9.  Defining RASopathy.

Authors:  Katherine A Rauen
Journal:  Dis Model Mech       Date:  2022-02-01       Impact factor: 5.758

Review 10.  Mitochondria in skin health, aging, and disease.

Authors:  Annapoorna Sreedhar; Leopoldo Aguilera-Aguirre; Keshav K Singh
Journal:  Cell Death Dis       Date:  2020-06-09       Impact factor: 8.469

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.